Exact Sciences Corp (EXAS) Misses Q1 Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Exact Sciences (EXAS) Spec Buy Reiterated at Benchmark; Co. Anything But Revenue and Earnings Story
May 1, 2014 2:57 PM EDTBenchmark maintained a Speculative Buy rating on Exact Sciences (NASDAQ: EXAS) with a price target of $25.00. Comments follow Q1 results.
"Revenues were $0.3 Million and EPS was ($0.23). That being said, Exact Sciences is anything but a revenue and earnings storyat least for now. The company made significant progress on two fronts. The publication of the results of the DEEP-C Study in the New England Journal of Medicine highlighted what the benefits of the... More
